TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05480150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram Oxalate Tablets
Description: Starting at 5mg qn, the treatment dose was titrated to 10-20mg qn within 1 week and maintained for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate Tablets
Description: Starting at 50mg qn, the treatment dose was titrated to 300-400mg qn within 10 days, and maintained the treatment for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurasidone
Description: Starting at 20mg qn, the treatment dose was titrated to 40mg qn within 6 days,and maintained the treatment for 4 weeks.
Study: NCT04731779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Cannabidiol oral product formulated in MCT (medium chain triglyceride) oil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral product formulated in MCT (medium chain triglyceride) oil
Study: NCT04838262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Stressors
Description: Sympathetic nervous system activity and blood pressure will be measured before, during, and after several acute laboratory-based cognitive (Stroop Color Word Test), emotional (International Affective Picture System), and physiological (Cold Pressor Test) stressors.
Study: NCT06018480

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Creatine Monohydrate
Description: The supplementation is the intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (Placebo)
Description: Placebo to Creatine Monohydrate
Study: NCT03141424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapering of inhaled corticosteroid (ICS) treatment
Description: Tapering of ICS treatment over 8 weeks. Follow-up over 52 weeks in total. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
Study: NCT06579742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Live Conscious Beyond Collagen
Description: Participants in the experimental arm will take 1 scoop (10.4 g) of Live Conscious Beyond Collagen supplement mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants in the placebo comparator arm will take 1 scoop (10.4 g) of the placebo product (Maltodextrin) mixed with 12 fl oz of water in the evening after their last meal of the day for 24 weeks.
Study: NCT06009081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: postural exercise
Description: The exercises consisted of 4-way neck isometric exercises and stretching exercises for the activation of deep cervical flexors (chin tuck exercise) and combined with this exercise. This protocol consisted of protocols studied in similar studies.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic exercise
Description: The walking program was carried out daily on a flat surface with a target of 7000 steps. This goal is based on the American College of Sports Medicine reports on the minimum recommended levels of physical activity required to achieve health benefits, which includes several design elements.
Study: NCT06580483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amalgam restoration
Description: An abutment tooth is restored on a side by amalgam plug
Study: NCT06366724

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine
Description: Pyridostigmine timeline:~Weeks 0-2: 20mg TID (1.67 mL TID)~Weeks 2-4: 40mg TID (3.33 mL TID)~Weeks 5-13: 60mg TID (5mL TID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine
Description: Pyridostigmine timeline:~Weeks 0-2: 20mg TID (1.67 mL TID)~Weeks 2-4: 40mg TID (3.33 mL TID)~Weeks 5-13: 60mg TID (5mL TID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Naltrexone
Description: LDN timeline:~Weeks 0-2: 1.5mg QD (1.5mL QD)~Weeks 2-4: 3.0mg QD (3.0mL QD)~Weeks 5-13: 4.5mg QD (4.5mL QD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-Dose Naltrexone
Description: LDN timeline:~Weeks 0-2: 1.5mg QD (1.5mL QD)~Weeks 2-4: 3.0mg QD (3.0mL QD)~Weeks 5-13: 4.5mg QD (4.5mL QD)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo timeline:~Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD)~Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD)~Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo timeline:~Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD)~Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD)~Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo timeline:~Weeks 0-2: 20mg TID (1.67mL TID)/1.5mg QD (1.5mL QD)~Weeks 2-4: 40mg TID (3.33mL TID)/3.0mg QD (3.0mL QD)~Weeks 5-13: 60mg TID (5mL TID)/4.5mg QD (4.5mL QD)
Study: NCT06580483

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nano-composite
Description: An abutment tooth is restored on a side by nano-composite
Study: NCT05449951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: In dry needling filiform needle without a bore is used to mimic acupuncture t beyond the use of medicines. On the basis of purpose process and skill level it differs from acupuncture. DN is frequently used to treat pain caused by musculoskeletal structures, including as myofascial pain disorders

Intervention type: OTHER
Group type: OTHER
Intervention: sustained stretching
Description: sustained stretching is a treatment protocol in which muscle goes into a stretch position for period of time which reduce spasticity
Study: NCT05886270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Housing Assessment/Safety Modifications
Description: A GHHI Assessor will complete three home visits to assess home injury hazards and provide a scope of work that includes home modifications that directly address each of the identified home injury hazards. The Assessor will also provide do-it-yourself education materials and injury prevention supplies to assist them in completing the modifications.
Study: NCT05968651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin nasal spray
Description: Single acute administration of 24 international units (IU) oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Single acute administration of 24 international units (IU) oxytocin
Study: NCT06060977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007
Description: Intravenous Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007
Description: Intravenous Infusion
Study: NCT04823377

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Patients receiving systemic anticancer treatment in their last days of life

Intervention type: OTHER
Group type: OTHER
Intervention: Optimization of the medical decision
Description: Impact of the use of an optimization device of the decision of cancer treatment on aggressiveness of end of life care
Study: NCT06072378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Value-manipulation
Description: During the decision-making task, different choices are assigned different values probabilistically.
Study: NCT03925077

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Movement-to-Music
Description: The M2M program has been developed for onsite instruction and will be repurposed into an eHealth version. The program is based on the positive effects of exercise and music on both physiological and psychosocial outcomes in people with disabilities. Investigators aim to advance our current M2M program by enabling more robust personalization features, allowing people with SCI to individualize their M2M program. Movement and tempo-based adaptations will also be available. A typical M2M session will consist of tailored movement routines starting with a warmup using range of motion exercises, followed by muscle strengthening, cardiorespiratory, and/or balance routines, and ending with a cool down emphasizing breathing and mindfulness.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Exercise Training
Description: The SET program is based on the NCHPAD 14-Weeks to a Healthier You program launched in 2008. Exercise videos including range of motion, muscle strengthening, cardio and balance routines performed both seated and standing have been developed and will be restructured for use in this study. The SET program will be delivered through the same platform as M2M.
Study: NCT05130970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Garadacimab
Description: Participants received garadacimab intravenous (IV) loading dose followed by 3 subcutaneous (SC) doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received a matching placebo IV loading dose, followed by 3 SC doses.
Study: NCT05620823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral; Tablet
Study: NCT06369259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: Given by PO
Study: NCT05936567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: oral; tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: oral; tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: oral; tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: oral; tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral; tablet
Study: NCT06126783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI311
Description: The first dose was 10 mg/kg, followed by 7 maintenance doses of 20 mg/kg, Q3W
Study: NCT05703854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.70/IL15-transduced CB-derived NK cells
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)
Study: NCT06576362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy
Description: Echoguided transuterine vaginal biopsy performed before myomectomy or hysterectomy
Study: NCT05972551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisphosphonate
Description: Administration determined by investigator according to the local standard of care
Study: NCT05756387

Intervention type: DEVICE
Intervention: Non-invasive ventilation
Description: NIV as in standard care
Study: NCT05121519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consume coffee
Description: Drink coffee regularly (recommend at least 1 cup of coffee per day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Avoid coffee
Description: Abstain from coffee and other caffeinated beverages
Study: NCT06017024

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microprocessor-controlled knee (MPK) assessment
Description: The subject will wear the microprocessor-controlled knee prosthesis for 4 weeks, and then reply questionnaires and achieve functional tests

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microprocessor-controlled knee (MPK) assessment
Description: The subject will wear the microprocessor-controlled knee prosthesis for 4 weeks, and then reply questionnaires and achieve functional tests
Study: NCT06304818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCTB14
Description: SCTB14,IV
Study: NCT05033054

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Participants will ingest a standard dose of SGLT2i prescribed by the standard of care physician.
Study: NCT05722002

Intervention type: DRUG
Group type: OTHER
Intervention: NSAID
Description: Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Ibuprofen 600 milligram (mg) by mouth every six hours as needed for pain (10 doses)~* Celecoxib 400 mg by mouth once then 200 mg every twelve hours as needed for pain (10 doses)~* Naproxen 500 mg by mouth once then 250 mg by mouth every eight hours as needed for pain (10 doses)

Intervention type: DRUG
Group type: OTHER
Intervention: Opioid
Description: Once randomized to this group the surgical team will elect for 1 of the following treatment options to be given:~* Oxycodone 5 mg by mouth every four to six hours as needed for pain, 10 doses~* Morphine 7.5 mg by mouth every four to six hours as needed for pain, 10 doses~* Hydromorphone 2 mg by mouth every four to six hours as needed for pain, 10 doses

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen
Description: Acetaminophen 1000 mg by mouth every 6 hours around the clock for the first three days after surgery then as needed thereafter (20 doses).
Study: NCT06401356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pelabresib
Description: Small molecule inhibitor of bromodomain and extraterminal (BET) protein
Study: NCT06416800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povorcitinib
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: Oral; Tablet
Study: NCT05091710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HF follow up care
Description: The intervention will consist of follow up phone calls and visits during which the CHWs will remind patients about upcoming visits, ensure patient has sufficient medications, review medication schedule and provide education as needed.

Intervention type: OTHER
Group type: OTHER
Intervention: HF Standard of Care (SOC)
Description: SOC after discharge for HF is to notify patients of a follow-up visit at the hospital/clinic - about 7 days after discharge and provide patients about 30 days of medications at discharge. If a patient does not return for a follow-up appointment, there are no systems to track this missed visit, or to trigger active attempts to contact patients. For patients who come back to their scheduled 7-day visit, there is generally a 14-day visit followed by a 28-day visit.
Study: NCT04789538

Intervention type: OTHER
Intervention: monofocal lens
Description: not applicable as patients are already implanted with the monofocal intraocular lens
Study: NCT05304338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Gargling with 10 mL 0.2% Chlorhexidine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oil Pulling
Description: In oil pulling therapy, a tablespoon of edible oil is placed in the mouth and swirled between the teeth for 15 to 20 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oil Pulling
Description: In oil pulling therapy, a tablespoon of edible oil is placed in the mouth and swirled between the teeth for 15 to 20 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oil Pulling
Description: In oil pulling therapy, a tablespoon of edible oil is placed in the mouth and swirled between the teeth for 15 to 20 minutes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: Gargling with 10 mL distilled water
Study: NCT04856722

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mini-PNL
Description: PCNL using miniature nephroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIRS
Description: RIRS using flexible ureteroscope. The procedure will be performed under general or regional anaesthesia under fluoroscopy guidance. Holmium Laser lithotripter will be used for stone fragmentation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SWL
Description: SWL using Dornier SII lithotripter. the procedure will be performed under sedoanalgesia, and fluoroscopy will be used for stone localization; for a maximum of 3 SWL session.
Study: NCT04490486

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSCs
Description: 100 x 106 (100 million) UCMSCs delivered via peripheral intravenous infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, a solution of 1% human serum albumin in Plasmalyte A, delivered via peripheral intravenous infusion
Study: NCT06639061

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hippocampal stimulation using repetitive transcranial magnetic stimulation (rTMS)
Description: We will use fMRI resting state data to personalize a TMS inhibitory stimulation to a cortical location that is the most strongly connected to a deeper left hippocampal target.~5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation using repetitive transcranial magnetic stimulation (rTMS)
Description: We will use fMRI resting state data to personalize a TMS sham stimulation to a cortical location with near zero connectivity to a deeper left hippocampal target. 5 once a week sessions of rTMS will be delivered at 1-Hz stimulation frequency for 15 minutes following trauma memory reactivation.
Study: NCT05899517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral lollipop with oxytocin (24IU)
Description: For oral oxytocin administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after oxytocin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral lollipop with oxytocin (24IU)
Description: For oral oxytocin administration, participants will be instructed to suck the lollipop medicated with 24IU oxytocin for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after oxytocin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral lollipop with placebo
Description: For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after placebo administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral lollipop with placebo
Description: For placebo administration, participants will be instructed to suck the placebo lollipop for 3 minutes and then to sit relaxed in a quiet room for 30 minutes prior to rate their mood (PANAS). Participants then start the self versus other touch task around 53 minutes after placebo administration.
Study: NCT05931341

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rosemary extract
Description: Softgel capsule including rosemary extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rosemary extract
Description: Softgel capsule including rosemary extract

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rosemary extract
Description: Softgel capsule including rosemary extract
Study: NCT05000008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Moderate aerobic and resistance exercise programe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Moderate aerobic and resistance exercise programe
Study: NCT05950919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TASKPEN
Description: The package of integrated HIV/NCD services:~1. Integrated non-communicable/HIV care (one stop shop for services)~2. WHO PEN protocols, algorithm, \& training materials adapted for Zambia~3. Access to cardio-metabolic condition screening \& laboratory monitoring~4. Non-communicable disease-focused electronic medical record module~5. Strengthened NCD medication supply chain
Study: NCT06577064

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral erector spinae plane block
Description: 30 ml of 0.2% ropivacaine will be injected in the plane between the ESM and sacrum on each side

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sacral erector spinae plane block
Description: 30 ml of 0.2% ropivacaine will be injected in the plane between the ESM and sacrum on each side